Transplant Rejection Treatment Comprehensive Study by Type (Hyperacute Transplant Rejection, Acute Transplant Rejection, Chronic Transplant Rejection), Drugs (Antirejection Medicines, Corticosteroids, Others) Players and Region - Global Market Outlook to 2026

Transplant Rejection Treatment Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Transplant Rejection Treatment Market Scope?
Transplant rejection is a process in which a transplant recipientsí immune system attacks the transplanted organ and tissue. Among all types of rejection type chronic rejection is taken over for many years. This person's body is constantly responding against the new organ and slowly damages the transplanted tissues or organs. Through this treatment making sure that transplanted organs or tissues operate properly.

The Transplant Rejection Treatment market study is being classified by Type (Hyperacute Transplant Rejection, Acute Transplant Rejection and Chronic Transplant Rejection) and major geographies with country level break-up.

This industry is witnessing an increasing number of new market entrants. Market key players are focusing on advanced digital technologies, improving efficiency, and other services. Market growth opportunities are captured by tracking the ongoing technological advancement, services development, and others. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Transplant Rejection Treatment market throughout the predicted period.

GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Astellas Pharma, Inc. (Japan), Pfizer, Inc. (United States), AbbVie, Inc. (United States), Teva Pharmaceuticals (Israel), Allergan plc (Ireland), Sanofi (France) and Zimmer Biomet (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Biolife Solutions (United States), Bristol-Myers Squibb Company (BMS) (United States) and Veloxis Pharmaceuticals (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Transplant Rejection Treatment market by Type, Application and Region.

On the basis of geography, the market of Transplant Rejection Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In Nov 2021, Novartis revealed an interim analysis of data from the CIRRUS-1 study. This analysis indicated that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant.


Influencing Market Trend
  • Rapid Advancement in Technological Development
  • Chronic Rejection is Becoming a Major Cause of Organ Transplant Failure
  • North America Expects High Growth in Lead Organ Transplant Rejection Medications Industry

Market Drivers
  • High Growth in Healthcare Spending and Improvements in Healthcare Infrastructure
  • High Growth in Geriatric Population

Opportunities
  • High Growth in Healthcare Expenditure
  • Increase in Government Expenditure
  • Kidney Transplant Offer High Growth Opportunities

Restraints
  • Lack of Proper Awareness in Under Developing Regions

Challenges
  • High-Cost Associated of Transplant Rejection Treatment


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Transplant Rejection Treatment Providers, Government Regulatory and Research Organizations and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Hyperacute Transplant Rejection
  • Acute Transplant Rejection
  • Chronic Transplant Rejection
By Drugs
  • Antirejection Medicines
  • Corticosteroids
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Growth in Healthcare Spending and Improvements in Healthcare Infrastructure
      • 3.2.2. High Growth in Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. High-Cost Associated of Transplant Rejection Treatment
    • 3.4. Market Trends
      • 3.4.1. Rapid Advancement in Technological Development
      • 3.4.2. Chronic Rejection is Becoming a Major Cause of Organ Transplant Failure
      • 3.4.3. North America Expects High Growth in Lead Organ Transplant Rejection Medications Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Transplant Rejection Treatment, by Type, Drugs and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Transplant Rejection Treatment (Value)
      • 5.2.1. Global Transplant Rejection Treatment by: Type (Value)
        • 5.2.1.1. Hyperacute Transplant Rejection
        • 5.2.1.2. Acute Transplant Rejection
        • 5.2.1.3. Chronic Transplant Rejection
      • 5.2.2. Global Transplant Rejection Treatment by: Drugs (Value)
        • 5.2.2.1. Antirejection Medicines
        • 5.2.2.2. Corticosteroids
        • 5.2.2.3. Others
      • 5.2.3. Global Transplant Rejection Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Transplant Rejection Treatment (Volume)
      • 5.3.1. Global Transplant Rejection Treatment by: Type (Volume)
        • 5.3.1.1. Hyperacute Transplant Rejection
        • 5.3.1.2. Acute Transplant Rejection
        • 5.3.1.3. Chronic Transplant Rejection
      • 5.3.2. Global Transplant Rejection Treatment by: Drugs (Volume)
        • 5.3.2.1. Antirejection Medicines
        • 5.3.2.2. Corticosteroids
        • 5.3.2.3. Others
      • 5.3.3. Global Transplant Rejection Treatment Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Australia
          • 5.3.3.2.6. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Transplant Rejection Treatment (Price)
      • 5.4.1. Global Transplant Rejection Treatment by: Type (Price)
  • 6. Transplant Rejection Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Astellas Pharma, Inc. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AbbVie, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceuticals (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Allergan plc (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Zimmer Biomet (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Transplant Rejection Treatment Sale, by Type, Drugs and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Transplant Rejection Treatment (Value)
      • 7.2.1. Global Transplant Rejection Treatment by: Type (Value)
        • 7.2.1.1. Hyperacute Transplant Rejection
        • 7.2.1.2. Acute Transplant Rejection
        • 7.2.1.3. Chronic Transplant Rejection
      • 7.2.2. Global Transplant Rejection Treatment by: Drugs (Value)
        • 7.2.2.1. Antirejection Medicines
        • 7.2.2.2. Corticosteroids
        • 7.2.2.3. Others
      • 7.2.3. Global Transplant Rejection Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Transplant Rejection Treatment (Volume)
      • 7.3.1. Global Transplant Rejection Treatment by: Type (Volume)
        • 7.3.1.1. Hyperacute Transplant Rejection
        • 7.3.1.2. Acute Transplant Rejection
        • 7.3.1.3. Chronic Transplant Rejection
      • 7.3.2. Global Transplant Rejection Treatment by: Drugs (Volume)
        • 7.3.2.1. Antirejection Medicines
        • 7.3.2.2. Corticosteroids
        • 7.3.2.3. Others
      • 7.3.3. Global Transplant Rejection Treatment Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Australia
          • 7.3.3.2.6. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Transplant Rejection Treatment (Price)
      • 7.4.1. Global Transplant Rejection Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Transplant Rejection Treatment: by Type(USD Million)
  • Table 2. Transplant Rejection Treatment Hyperacute Transplant Rejection , by Region USD Million (2015-2020)
  • Table 3. Transplant Rejection Treatment Acute Transplant Rejection , by Region USD Million (2015-2020)
  • Table 4. Transplant Rejection Treatment Chronic Transplant Rejection , by Region USD Million (2015-2020)
  • Table 5. Transplant Rejection Treatment: by Drugs(USD Million)
  • Table 6. Transplant Rejection Treatment Antirejection Medicines , by Region USD Million (2015-2020)
  • Table 7. Transplant Rejection Treatment Corticosteroids , by Region USD Million (2015-2020)
  • Table 8. Transplant Rejection Treatment Others , by Region USD Million (2015-2020)
  • Table 9. South America Transplant Rejection Treatment, by Country USD Million (2015-2020)
  • Table 10. South America Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 11. South America Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 12. Brazil Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 13. Brazil Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 14. Argentina Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 15. Argentina Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 16. Rest of South America Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 17. Rest of South America Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 18. Asia Pacific Transplant Rejection Treatment, by Country USD Million (2015-2020)
  • Table 19. Asia Pacific Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 20. Asia Pacific Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 21. China Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 22. China Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 23. Japan Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 24. Japan Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 25. India Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 26. India Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 27. South Korea Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 28. South Korea Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 29. Australia Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 30. Australia Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 31. Rest of Asia-Pacific Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 32. Rest of Asia-Pacific Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 33. Europe Transplant Rejection Treatment, by Country USD Million (2015-2020)
  • Table 34. Europe Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 35. Europe Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 36. Germany Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 37. Germany Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 38. France Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 39. France Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 40. Italy Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 41. Italy Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 42. United Kingdom Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 43. United Kingdom Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 44. Netherlands Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 45. Netherlands Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 46. Rest of Europe Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 47. Rest of Europe Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 48. MEA Transplant Rejection Treatment, by Country USD Million (2015-2020)
  • Table 49. MEA Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 50. MEA Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 51. Middle East Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 52. Middle East Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 53. Africa Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 54. Africa Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 55. North America Transplant Rejection Treatment, by Country USD Million (2015-2020)
  • Table 56. North America Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 57. North America Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 58. United States Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 59. United States Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 60. Canada Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 61. Canada Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 62. Mexico Transplant Rejection Treatment, by Type USD Million (2015-2020)
  • Table 63. Mexico Transplant Rejection Treatment, by Drugs USD Million (2015-2020)
  • Table 64. Transplant Rejection Treatment Sales: by Type(K Tons)
  • Table 65. Transplant Rejection Treatment Sales Hyperacute Transplant Rejection , by Region K Tons (2015-2020)
  • Table 66. Transplant Rejection Treatment Sales Acute Transplant Rejection , by Region K Tons (2015-2020)
  • Table 67. Transplant Rejection Treatment Sales Chronic Transplant Rejection , by Region K Tons (2015-2020)
  • Table 68. Transplant Rejection Treatment Sales: by Drugs(K Tons)
  • Table 69. Transplant Rejection Treatment Sales Antirejection Medicines , by Region K Tons (2015-2020)
  • Table 70. Transplant Rejection Treatment Sales Corticosteroids , by Region K Tons (2015-2020)
  • Table 71. Transplant Rejection Treatment Sales Others , by Region K Tons (2015-2020)
  • Table 72. South America Transplant Rejection Treatment Sales, by Country K Tons (2015-2020)
  • Table 73. South America Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 74. South America Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 75. Brazil Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 76. Brazil Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 77. Argentina Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 78. Argentina Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 79. Rest of South America Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 80. Rest of South America Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 81. Asia Pacific Transplant Rejection Treatment Sales, by Country K Tons (2015-2020)
  • Table 82. Asia Pacific Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 83. Asia Pacific Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 84. China Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 85. China Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 86. Japan Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 87. Japan Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 88. India Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 89. India Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 90. South Korea Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 91. South Korea Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 92. Australia Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 93. Australia Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 94. Rest of Asia-Pacific Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 95. Rest of Asia-Pacific Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 96. Europe Transplant Rejection Treatment Sales, by Country K Tons (2015-2020)
  • Table 97. Europe Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 98. Europe Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 99. Germany Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 100. Germany Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 101. France Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 102. France Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 103. Italy Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 104. Italy Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 105. United Kingdom Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 106. United Kingdom Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 107. Netherlands Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 108. Netherlands Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 109. Rest of Europe Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 110. Rest of Europe Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 111. MEA Transplant Rejection Treatment Sales, by Country K Tons (2015-2020)
  • Table 112. MEA Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 113. MEA Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 114. Middle East Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 115. Middle East Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 116. Africa Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 117. Africa Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 118. North America Transplant Rejection Treatment Sales, by Country K Tons (2015-2020)
  • Table 119. North America Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 120. North America Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 121. United States Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 122. United States Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 123. Canada Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 124. Canada Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 125. Mexico Transplant Rejection Treatment Sales, by Type K Tons (2015-2020)
  • Table 126. Mexico Transplant Rejection Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 127. Transplant Rejection Treatment: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Transplant Rejection Treatment: by Type(USD Million)
  • Table 139. Transplant Rejection Treatment Hyperacute Transplant Rejection , by Region USD Million (2021-2026)
  • Table 140. Transplant Rejection Treatment Acute Transplant Rejection , by Region USD Million (2021-2026)
  • Table 141. Transplant Rejection Treatment Chronic Transplant Rejection , by Region USD Million (2021-2026)
  • Table 142. Transplant Rejection Treatment: by Drugs(USD Million)
  • Table 143. Transplant Rejection Treatment Antirejection Medicines , by Region USD Million (2021-2026)
  • Table 144. Transplant Rejection Treatment Corticosteroids , by Region USD Million (2021-2026)
  • Table 145. Transplant Rejection Treatment Others , by Region USD Million (2021-2026)
  • Table 146. South America Transplant Rejection Treatment, by Country USD Million (2021-2026)
  • Table 147. South America Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 148. South America Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 149. Brazil Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 150. Brazil Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 151. Argentina Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 152. Argentina Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 153. Rest of South America Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 154. Rest of South America Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 155. Asia Pacific Transplant Rejection Treatment, by Country USD Million (2021-2026)
  • Table 156. Asia Pacific Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 157. Asia Pacific Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 158. China Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 159. China Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 160. Japan Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 161. Japan Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 162. India Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 163. India Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 164. South Korea Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 165. South Korea Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 166. Australia Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 167. Australia Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 168. Rest of Asia-Pacific Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 169. Rest of Asia-Pacific Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 170. Europe Transplant Rejection Treatment, by Country USD Million (2021-2026)
  • Table 171. Europe Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 172. Europe Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 173. Germany Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 174. Germany Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 175. France Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 176. France Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 177. Italy Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 178. Italy Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 179. United Kingdom Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 180. United Kingdom Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 181. Netherlands Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 182. Netherlands Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 183. Rest of Europe Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 184. Rest of Europe Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 185. MEA Transplant Rejection Treatment, by Country USD Million (2021-2026)
  • Table 186. MEA Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 187. MEA Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 188. Middle East Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 189. Middle East Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 190. Africa Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 191. Africa Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 192. North America Transplant Rejection Treatment, by Country USD Million (2021-2026)
  • Table 193. North America Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 194. North America Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 195. United States Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 196. United States Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 197. Canada Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 198. Canada Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 199. Mexico Transplant Rejection Treatment, by Type USD Million (2021-2026)
  • Table 200. Mexico Transplant Rejection Treatment, by Drugs USD Million (2021-2026)
  • Table 201. Transplant Rejection Treatment Sales: by Type(K Tons)
  • Table 202. Transplant Rejection Treatment Sales Hyperacute Transplant Rejection , by Region K Tons (2021-2026)
  • Table 203. Transplant Rejection Treatment Sales Acute Transplant Rejection , by Region K Tons (2021-2026)
  • Table 204. Transplant Rejection Treatment Sales Chronic Transplant Rejection , by Region K Tons (2021-2026)
  • Table 205. Transplant Rejection Treatment Sales: by Drugs(K Tons)
  • Table 206. Transplant Rejection Treatment Sales Antirejection Medicines , by Region K Tons (2021-2026)
  • Table 207. Transplant Rejection Treatment Sales Corticosteroids , by Region K Tons (2021-2026)
  • Table 208. Transplant Rejection Treatment Sales Others , by Region K Tons (2021-2026)
  • Table 209. South America Transplant Rejection Treatment Sales, by Country K Tons (2021-2026)
  • Table 210. South America Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 211. South America Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 212. Brazil Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 213. Brazil Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 214. Argentina Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 215. Argentina Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 216. Rest of South America Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 217. Rest of South America Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 218. Asia Pacific Transplant Rejection Treatment Sales, by Country K Tons (2021-2026)
  • Table 219. Asia Pacific Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 220. Asia Pacific Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 221. China Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 222. China Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 223. Japan Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 224. Japan Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 225. India Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 226. India Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 227. South Korea Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 228. South Korea Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 229. Australia Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 230. Australia Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 231. Rest of Asia-Pacific Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 232. Rest of Asia-Pacific Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 233. Europe Transplant Rejection Treatment Sales, by Country K Tons (2021-2026)
  • Table 234. Europe Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 235. Europe Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 236. Germany Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 237. Germany Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 238. France Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 239. France Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 240. Italy Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 241. Italy Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 242. United Kingdom Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 243. United Kingdom Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 244. Netherlands Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 245. Netherlands Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 246. Rest of Europe Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 247. Rest of Europe Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 248. MEA Transplant Rejection Treatment Sales, by Country K Tons (2021-2026)
  • Table 249. MEA Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 250. MEA Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 251. Middle East Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 252. Middle East Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 253. Africa Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 254. Africa Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 255. North America Transplant Rejection Treatment Sales, by Country K Tons (2021-2026)
  • Table 256. North America Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 257. North America Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 258. United States Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 259. United States Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 260. Canada Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 261. Canada Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 262. Mexico Transplant Rejection Treatment Sales, by Type K Tons (2021-2026)
  • Table 263. Mexico Transplant Rejection Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 264. Transplant Rejection Treatment: by Type(USD/Units)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Transplant Rejection Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Transplant Rejection Treatment: by Drugs USD Million (2015-2020)
  • Figure 6. South America Transplant Rejection Treatment Share (%), by Country
  • Figure 7. Asia Pacific Transplant Rejection Treatment Share (%), by Country
  • Figure 8. Europe Transplant Rejection Treatment Share (%), by Country
  • Figure 9. MEA Transplant Rejection Treatment Share (%), by Country
  • Figure 10. North America Transplant Rejection Treatment Share (%), by Country
  • Figure 11. Global Transplant Rejection Treatment: by Type K Tons (2015-2020)
  • Figure 12. Global Transplant Rejection Treatment: by Drugs K Tons (2015-2020)
  • Figure 13. South America Transplant Rejection Treatment Share (%), by Country
  • Figure 14. Asia Pacific Transplant Rejection Treatment Share (%), by Country
  • Figure 15. Europe Transplant Rejection Treatment Share (%), by Country
  • Figure 16. MEA Transplant Rejection Treatment Share (%), by Country
  • Figure 17. North America Transplant Rejection Treatment Share (%), by Country
  • Figure 18. Global Transplant Rejection Treatment: by Type USD/Units (2015-2020)
  • Figure 19. Global Transplant Rejection Treatment share by Players 2020 (%)
  • Figure 20. Global Transplant Rejection Treatment share by Players (Top 3) 2020(%)
  • Figure 21. Global Transplant Rejection Treatment share by Players (Top 5) 2020(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 27. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 29. Astellas Pharma, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Astellas Pharma, Inc. (Japan) Revenue: by Geography 2020
  • Figure 31. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. AbbVie, Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 36. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 37. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 38. Allergan plc (Ireland) Revenue: by Geography 2020
  • Figure 39. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 40. Sanofi (France) Revenue: by Geography 2020
  • Figure 41. Zimmer Biomet (United States) Revenue, Net Income and Gross profit
  • Figure 42. Zimmer Biomet (United States) Revenue: by Geography 2020
  • Figure 43. Global Transplant Rejection Treatment: by Type USD Million (2021-2026)
  • Figure 44. Global Transplant Rejection Treatment: by Drugs USD Million (2021-2026)
  • Figure 45. South America Transplant Rejection Treatment Share (%), by Country
  • Figure 46. Asia Pacific Transplant Rejection Treatment Share (%), by Country
  • Figure 47. Europe Transplant Rejection Treatment Share (%), by Country
  • Figure 48. MEA Transplant Rejection Treatment Share (%), by Country
  • Figure 49. North America Transplant Rejection Treatment Share (%), by Country
  • Figure 50. Global Transplant Rejection Treatment: by Type K Tons (2021-2026)
  • Figure 51. Global Transplant Rejection Treatment: by Drugs K Tons (2021-2026)
  • Figure 52. South America Transplant Rejection Treatment Share (%), by Country
  • Figure 53. Asia Pacific Transplant Rejection Treatment Share (%), by Country
  • Figure 54. Europe Transplant Rejection Treatment Share (%), by Country
  • Figure 55. MEA Transplant Rejection Treatment Share (%), by Country
  • Figure 56. North America Transplant Rejection Treatment Share (%), by Country
  • Figure 57. Global Transplant Rejection Treatment: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc (United Kingdom)
  • Novartis AG (Switzerland)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Astellas Pharma, Inc. (Japan)
  • Pfizer, Inc. (United States)
  • AbbVie, Inc. (United States)
  • Teva Pharmaceuticals (Israel)
  • Allergan plc (Ireland)
  • Sanofi (France)
  • Zimmer Biomet (United States)
Additional players considered in the study are as follows:
Biolife Solutions (United States) , Bristol-Myers Squibb Company (BMS) (United States) , Veloxis Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Dec 2021 228 Pages 55 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Transplant Rejection Treatment market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Transplant Rejection Treatment market are GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Astellas Pharma, Inc. (Japan), Pfizer, Inc. (United States), AbbVie, Inc. (United States), Teva Pharmaceuticals (Israel), Allergan plc (Ireland), Sanofi (France) and Zimmer Biomet (United States), to name a few.
In this highly competitive & fast evolving Transplant Rejection Treatment industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Transplant Rejection Treatment Market Report?